EA201101304A1 - Новая кристаллическая форма vi агомелатина, ее получение и применение - Google Patents

Новая кристаллическая форма vi агомелатина, ее получение и применение

Info

Publication number
EA201101304A1
EA201101304A1 EA201101304A EA201101304A EA201101304A1 EA 201101304 A1 EA201101304 A1 EA 201101304A1 EA 201101304 A EA201101304 A EA 201101304A EA 201101304 A EA201101304 A EA 201101304A EA 201101304 A1 EA201101304 A1 EA 201101304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agomelatin
reception
application
crystal form
crystalline form
Prior art date
Application number
EA201101304A
Other languages
English (en)
Other versions
EA019127B1 (ru
Inventor
Ханьбинь Шань
Пэн Чжан
Чжэдун Юань
Сюйдун Цзян
Ю Хуан
Сюйбо Ван
Сюйфэн Као
Синдун Чэн
Сиун Ю
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41370233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201101304A1 publication Critical patent/EA201101304A1/ru
Publication of EA019127B1 publication Critical patent/EA019127B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение обеспечивает новую кристаллическую форму агомелатина, ее получение и применение. Диаграмма рентгеновской порошковой дифрактометрии кристаллической формы агомелатина показывает основные пики при углах дифракции 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° и 31.93°. Упомянутая новая кристаллическая форма отличается высокой чистотой, стабильностью и хорошей воспроизводимостью и поэтому является выгодной для фармацевтических препаратов. К тому же, стабильность и растворимость упомянутой кристаллической формы также выше, чем у некоторых существующих кристаллических форм.
EA201101304A 2009-03-10 2010-03-09 Новая кристаллическая форма vi агомелатина, ее получение и применение EA019127B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910047329.2A CN101585779B (zh) 2009-03-10 2009-03-10 阿戈美拉汀的晶型vi及其制备方法和应用
PCT/CN2010/070931 WO2010102554A1 (zh) 2009-03-10 2010-03-09 阿戈美拉汀的新晶型ⅵ及其制备方法和应用

Publications (2)

Publication Number Publication Date
EA201101304A1 true EA201101304A1 (ru) 2012-04-30
EA019127B1 EA019127B1 (ru) 2014-01-30

Family

ID=41370233

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101304A EA019127B1 (ru) 2009-03-10 2010-03-09 Новая кристаллическая форма vi агомелатина, ее получение и применение

Country Status (27)

Country Link
US (1) US8614251B2 (ru)
EP (1) EP2431355A4 (ru)
JP (1) JP2012519715A (ru)
KR (1) KR20110123266A (ru)
CN (1) CN101585779B (ru)
AP (1) AP3049A (ru)
AU (1) AU2010223720B2 (ru)
BR (1) BRPI1013249A2 (ru)
CA (1) CA2754276A1 (ru)
CL (1) CL2011002231A1 (ru)
CO (1) CO6410293A2 (ru)
CR (1) CR20110457A (ru)
CU (1) CU20110162A7 (ru)
EA (1) EA019127B1 (ru)
EC (1) ECSP11011309A (ru)
GE (1) GEP20146114B (ru)
HN (1) HN2011002408A (ru)
IL (1) IL214683A0 (ru)
MA (1) MA33100B1 (ru)
MX (1) MX2011009339A (ru)
NI (1) NI201100167A (ru)
PE (1) PE20120653A1 (ru)
SG (2) SG173692A1 (ru)
TN (1) TN2011000426A1 (ru)
UA (1) UA100476C2 (ru)
WO (1) WO2010102554A1 (ru)
ZA (1) ZA201106049B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN102190595A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102557979B (zh) * 2010-12-16 2014-11-26 北大方正集团有限公司 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine

Also Published As

Publication number Publication date
KR20110123266A (ko) 2011-11-14
ECSP11011309A (es) 2011-10-31
EP2431355A4 (en) 2012-08-08
US8614251B2 (en) 2013-12-24
WO2010102554A1 (zh) 2010-09-16
HN2011002408A (es) 2014-06-23
AU2010223720B2 (en) 2012-05-03
EA019127B1 (ru) 2014-01-30
CU20110162A7 (es) 2012-02-15
US20120004313A1 (en) 2012-01-05
CN101585779B (zh) 2014-04-02
PE20120653A1 (es) 2012-06-14
SG177886A1 (en) 2012-02-28
MA33100B1 (fr) 2012-03-01
AU2010223720A1 (en) 2011-09-08
GEP20146114B (en) 2014-07-10
SG173692A1 (en) 2011-09-29
CO6410293A2 (es) 2012-03-30
CR20110457A (es) 2011-09-21
BRPI1013249A2 (pt) 2016-04-05
JP2012519715A (ja) 2012-08-30
CA2754276A1 (en) 2010-09-16
TN2011000426A1 (en) 2013-03-27
CN101585779A (zh) 2009-11-25
NI201100167A (es) 2012-01-11
AP3049A (en) 2014-11-30
IL214683A0 (en) 2011-11-30
EP2431355A1 (en) 2012-03-21
MX2011009339A (es) 2011-09-27
CL2011002231A1 (es) 2012-02-03
UA100476C2 (en) 2012-12-25
ZA201106049B (en) 2012-10-31
AP2011005914A0 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
EA201101304A1 (ru) Новая кристаллическая форма vi агомелатина, ее получение и применение
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
PH12015502825B1 (en) Crystals
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
RU2016146119A (ru) Новый кристалл тетрациклического соединения
EA201101208A1 (ru) Гидрогалогенидный комплекс агомелатина и его получение
EA201201294A1 (ru) Гидрат гидрохлорида агомелатина и его получение
EA200801777A1 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
RU2015114085A (ru) Кристаллические формы производных дигидропиримидина
RS53001B (en) DELTA CRYSTAL FORM OF ARGININE SALT PERINDOPRIL, PROCEDURE FOR ITS MANUFACTURE AND PHARMACEUTICAL MIXTURES CONTAINING IT
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
EA201290156A1 (ru) Комплексы вилдаглиптина с неорганической солью
ATE479728T1 (de) Neue kristallphase eines benzimidazolon-azo- pigments
WO2012044189A8 (en) A new hydrated crystalline form of perindopril erbumine, methods for its preparation and its use in pharmaceutical preparations
TH120304A (th) รูปแบบที่เป็นผลึก vi แบบใหม่ของอะโกเมลาทีน, การเตรียม และการใช้ของสิ่งนี้
UA59402U (ru) Кристаллический состав комбинированного лекарственного препарата анальгетического, противовоспалительного и жаропонижающего действия
TH120304B (th) รูปแบบที่เป็นผลึก vi แบบใหม่ของอะโกเมลาทีน, การเตรียม และการใช้ของสิ่งนี้
UA108849C2 (xx) Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетаміду

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU